Prostate Cancer Clinical Trials in Raleigh, NC

Prostate Cancer Clinical Trials in Raleigh, NC

View the best 10 prostate cancer medical studies in Raleigh, North Carolina. Access promising new therapies by applying to a Raleigh-based Prostate Cancer clinical trial.

Trials in Raleigh, North Carolina

Here are the top 10 medical studies for prostate cancer in Raleigh, North Carolina

Image of University of Alabama at Birmingham (UAB) in Birmingham, United States.

Standard of Care Proton Therapy +3 More

Proton Beam Therapy

Recruiting1 award
This trial compares the quality of life, toxicity, and disease control of men with prostate cancer treated with proton therapy vs. IMRT.
Image of Arizona Urology Specialists, PLLC in Tucson, United States.

Relugolix +1 More

Hormone Therapy

Recruiting2 awardsPhase 3
This trial compared the safety and heart-related risks of two hormone-lowering medications, relugolix and leuprolide acetate, in adults with prostate cancer. These drugs help manage cancer by reducing testosterone levels. The study was discontinued, but patients can continue their treatment for a certain period. Relugolix is the first oral medication of its kind and was approved by the FDA based on previous study results.
Image of Urological Associates of Southern Arizona, PC in Tucson, United States.

Enzalutamide

Antiandrogen

Recruiting1 awardPhase 3
This trial is testing a new drug to treat prostate cancer that has not spread. They will be testing how well it works and if it is safe.
Image of Tower Urology, in Los Angeles, United States.

Debio 4228

Anti-tumor antibiotic

Recruiting1 awardPhase 2
This trial aims to understand how the drug Debio 4228 moves through and affects the body.
Image of Call for Information (Investigational Site 0005) in Los Angeles, United States.

Pembrolizumab +7 More

Checkpoint Inhibitor

Recruiting1 awardPhase 1 & 2
This trial tests pembrolizumab combined with other drugs in patients with advanced prostate cancer that doesn't respond to usual treatments. The treatment works by boosting the immune system to better attack cancer cells. Pembrolizumab has been previously tested in combination with chemotherapy for other cancers, showing improved response rates and progression-free survival.
Image of UC San Diego Moores Cancer Center in La Jolla, United States.

Olaparib +1 More

PARP Inhibitor

Recruiting1 awardPhase 1 & 2
This trial is testing olaparib, a PARP inhibitor, as a possible treatment for metastatic castration-resistant prostate cancer. The trial will also study the best dose of olaparib and the side effects of the combination treatment.
Image of Research Site in La Jolla, United States.

Capivasertib +1 More

AKT Inhibitor

Recruiting1 awardPhase 3
This trial will compare the efficacy of capivasertib+abiraterone+androgen deprivation therapy to placebo+abiraterone+androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC) whose tumours are PTEN-deficient. The primary endpoint is radiographic progression-free survival.
Image of Sarah Cannon Research Institute in Denver, United States.

ST101

Virus Therapy

Recruiting1 awardPhase 1 & 2
This trial tests a new drug, ST101, given to patients with advanced cancers who haven't responded to other treatments. The study aims to find the safest and most effective dose. It includes patients with specific types of breast cancer, melanoma, brain cancer, and prostate cancer.
Image of Mayo Clinic Hospital in Phoenix, United States.

Multiparametric Magnetic Resonance Imaging

Diagnostic Test

Recruiting1 award1 criteria
This trial looks at how well MRI works in finding and staging prostate cancer, which may help treatment planning.
Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

Pembrolizumab

Checkpoint Inhibitor

Recruiting2 awardsPhase 2
This trial is testing the efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer. The study will also compare the pre-treatment and at-progression metastatic tumor biopsies to investigate the molecular correlates of resistance and sensitivity to pembrolizumab.

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.